...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis >Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
【24h】

Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.

机译：抗CD20单克隆抗体（利妥昔单抗）治疗的非霍奇金淋巴瘤患者中活化的血小板依赖性趋化因子升高。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study measured and compared levels of some chemokines in patients with rituximab-treated non-Hodgkin lymphoma because they may participate in the mechanism of efficacy of rituximab in non-Hodgkin lymphoma patients. Monocytic chemotactant protein-1, RANTES (regulated on activation, normally T-cell expressed and secreted), eotaxin, interleukin-8, neutrophil-activating protein-78, stromal cell-derived factor-1, and growth-regulating oncogene-alpha in patients with rituximab-treated non-Hodgkin lymphoma were measured by enzyme-linked immunosorbent assay. Levels of RANTES were higher in non-Hodgkin lymphoma patients than in controls. Levels of monocytic chemotactant protein-1, RANTES, and neutrophil-activating protein-78 were significantly elevated before and after chemotherapy with rituximab treatment. However, the level of stromal cell-derived factor-1 did not exhibit a significant change. Before to after chemotherapy without rituximab treatment, all chemokine levels did not exhibit significant changes. These findings suggest that activated platelet-dependent chemokines such as RANTES and neutrophil-activating protein-78 may modulate the efficacy of rituximab in antibody-dependent cellular cytotoxity.
机译：这项研究测量并比较了利妥昔单抗治疗的非霍奇金淋巴瘤患者中某些趋化因子的水平，因为它们可能参与了利妥昔单抗在非霍奇金淋巴瘤患者中的疗效机制。单核细胞趋化蛋白1，RANTES（在激活时受调节，通常是T细胞表达和分泌），嗜酸性粒细胞趋化因子，白介素8，嗜中性白细胞激活蛋白78，基质细胞衍生因子1和生长调节癌基因α。利妥昔单抗治疗的非霍奇金淋巴瘤患者通过酶联免疫吸附测定进行了测定。非霍奇金淋巴瘤患者的RANTES水平高于对照组。利妥昔单抗治疗的化疗前后，单核细胞趋化蛋白-1，RANTES和中性粒细胞活化蛋白-78的水平显着升高。但是，基质细胞衍生因子1的水平没有显示出明显的变化。未经利妥昔单抗治疗的化疗前至化疗后，所有趋化因子水平均未出现明显变化。这些发现表明，活化的血小板依赖性趋化因子，例如RANTES和中性粒细胞活化蛋白78，可能会调节利妥昔单抗在抗体依赖性细胞毒性中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号